Welcome to the New & Improved AmericanChemistry.com

  • Read time: 3 minutes
  • Blog Post

Croda’s Lipid Nanoparticle Technology Provides Critical Foundation for Pfizer-BioNTech COVID-19 Vaccine

Over the past decade, Croda Health Care’s Avanti business unit has focused medical research and development on its Lipid Nanoparticle (LNP) delivery technology, to address stability and delivery issues associated with mRNA-based vaccines.

Avanti utilized its LNP technology to enable the rapid clinical development of the Pfizer-BioNTech COVID-19 vaccine. Avanti was the first company to supply clinical and commercial quantities of this critical lipid technology that enables the targeted release of the mRNA vaccine to muscle tissue. Avanti worked closely with Pfizer-BioNTech to support the vaccine clinical trials, help gain emergency FDA authorizations, and provide a commercially viable solution.

Croda Avanti Lab

As a result of the Avanti LNP technology, Pfizer-BioNTech announced it would supply 300 million vaccines to the United States government to assist in overcoming the COVID-19 pandemic. Without access to the necessary materials to conduct clinical trials, as well as a commercial supply of this lipid technology to manufacture the vaccine, it is likely that many more lives may have been lost to the virus.

Over the past eight months, Croda Health Care and Avanti have reprioritized investment, resources, and other projects to focus on reliably and sustainably supplying high-quality vaccine components to meet demand while continuing to innovate new processes and technologies to benefit the health and wellness of the world’s population. By enabling a reliable supply of high-quality vaccine components, the chemistry developed by Avanti can help enhance quality of life for people around the world, as vaccinated populations are able to begin to return to socialization and reengage in the workforce.

Additionally, the success of the COVID-19 vaccines are likely to help propel the Avanti technology forward at an accelerated pace, and the LNP delivery systems can help in the development of future vaccines and other medical treatments. Croda’s lipid technologies are at the core of the company’s purpose, “Smart science to improve livesTM,” and play an important role in helping Croda reach its target of supporting the immunization agenda of the World Health Organization (WHO). By 2030, Croda is looking to contribute to the successful development and commercialization of at least 25 percent of the pipeline vaccines listed by the WHO.

About the Author
American Chemistry Council

The American Chemistry Council (ACC) represents the leading companies engaged in the multibillion-dollar business of chemistry. ACC members apply the science of chemistry to make innovative products, technologies and services that make people's lives better, healthier and safer. ACC is committed to improved environmental, health, safety and security performance through Responsible Care®; common sense advocacy addressing major public policy issues; and health and environmental research and product testing. ACC members and chemistry companies are among the largest investors in research and development, and are advancing products, processes and technologies to address climate change, enhance air and water quality, and progress toward a more sustainable, circular economy.

We use cookies to personalize content and ads, to provide social media features, and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.

Privacy Policy - Terms & Conditions